ViewRay Systems, Inc. develops MRIdian A3i, an MRI-guided radiation therapy system designed to help clinicians visualize and target cancer with detailed soft-tissue imaging. Unlike conventional imaging approaches that may rely on implanted markers, MRIdian A3i uses diagnostic-quality MRI to support precise treatment planning, real-time tissue tracking, and automated beam control during radiation delivery. The company presents the system as a way to adapt treatment to patient anatomy and accurately direct radiation to a target.

ViewRay’s website provides information about the MRIdian A3i system and treatment centers, along with resources for patients and clinicians. These include patient stories, scientific presentations, webinars, and information about cancers treated with the technology, including pancreatic, prostate, lung, liver, breast, and oligometastatic cancers. The company also shares evidence and clinical perspectives on treatment outcomes, including research concerning side effects and survival. ViewRay supports access to information for healthcare providers, patients, investors, and prospective employees through its online resources and contact channels.